PET/MR, PET/CT and Whole Body MR in Newly Diagnosed Acute Myeloid Leukemia (AML)

Who is this study for? Patients with newly diagnosed acute myeloid leukemia

What treatments are being studied? Computed Tomography+Diffusion Weighted Imaging+Fludeoxyglucose F-18+Gadolinium+Magnetic Resonance Imaging+Positron Emission Tomography+Three-Dimensional Spoiled Gradient MRI

Status: Recruiting

Location: See location...

Intervention Type: Procedure, Drug, Radiation

Study Type: Interventional

Study Phase: Phase 1

SUMMARY

This pilot phase I trial studies how well positron emission tomography (PET)/magnetic resonance imaging (MRI), fludeoxyglucose F-18 (18F-FDG) PET/computed tomography (CT), and whole body MRI work in finding extramedullary myeloid leukemia in patients with newly diagnosed acute myeloid leukemia. Extramedullary myeloid leukemia is a type of cancer found outside of the bone marrow and can be hard to detect with routine bone marrow monitoring, such as bone marrow aspirations. Diagnostic procedures, such as PET/MRI, 18F-FDG PET/CT and whole body MRI, may help find and diagnose extramedullary myeloid leukemia in patients with newly diagnosed acute myeloid leukemia.

Eligibility

Participation Requirements

Sex: All

Minimum Age: 18

Healthy Volunteers: f

View:

• Patients with newly diagnosed AML

• Non-English speaking subjects will be included. Verbal Translation Preparative Sheet (VTPS) short form will be utilized in consenting non-English speaking subjects.

Locations

United States

Texas

M D Anderson Cancer Center

RECRUITING

Houston

Contact Information

Primary

Dawid Schellingerhout, MD

dawid.schellingerhout@mdanderson.org

(713) 794-5673

Time Frame

Start Date: 2020-07-15

Estimated Completion Date: 2025-09-15

Participants

Target number of participants: 55

Treatments

Experimental: Diagnostic (18F-FDG PET/CT, whole body PET/MRI)

Patients receive gadolinium IV and undergo whole body PET/MRI comprising diffusion weighted imaging and 3D FSPGR-DE with and without fiducial markers. Patients then undergo 18F-FDG PET/CT before start treatment for acute myeloid leukemia.

Authors

Vikas Kundra

Related Therapeutic Areas

Acute Myeloid Leukemia (AML)

Leukemia

Acute Promyelocytic Leukemia

Similar Clinical Trials

View All

PET/MR, PET/CT and Whole Body MR in Newly Diagnosed Acute Myeloid Leukemia (AML)

Similar Clinical Trials

A Single-Center Prospective Cohort Study to Evaluate the Efficacy and Safety of Intensifying Treatment with Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia (non-APL) and Exhibiting Lower Early Peripheral Blast Clearance Rate After Standard Intensive Induction Chemotherapy

A Single-Center Prospective Cohort Study to Evaluate the Efficacy and Safety of Intensifying Treatment with Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia (non-APL) and Exhibiting Lower Early Peripheral Blast Clearance Rate After Standard Intensive Induction Chemotherapy

Frontline Oral Arsenic Trioxide-based Induction in Newly Diagnosed Acute Promyelocytic Leukaemia

Frontline Oral Arsenic Trioxide-based Induction in Newly Diagnosed Acute Promyelocytic Leukaemia

A Randomized Phase 2 Clinical Trial to Evaluate the Activity of ATRA in Combination With Anastrozole in Pre-operative Phase of Operable HR-positive/HER2-negative Early Breast Cancer (ATRA)

A Randomized Phase 2 Clinical Trial to Evaluate the Activity of ATRA in Combination With Anastrozole in Pre-operative Phase of Operable HR-positive/HER2-negative Early Breast Cancer (ATRA)